Bioniche Life Sciences Inc. (BNC) Release: Most Effective Strategy for Managing E. coli O157:H7 in Beef is a Combination of a Pre-Harvest Intervention and Several Processing Interventions
5/29/2012 9:43:27 AM
BELLEVILLE, ON, May 28, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today announced that a Public Health Agency
of Canada study assessing the effects of various interventions on the
management of E. coli O157:H7 in Canadian beef came to a favourable conclusion with regard to
pre-harvest vaccines such as the Company's EconicheTM cattle vaccine. The study, "A risk assessment model for Escherichia coli O157:H7 in ground beef and beef cuts in Canada: Evaluating the effects
of interventions", has been accepted for publication in an upcoming
issue of Food Control (2012) and is now available on-line. Its authors are Ben A. Smith,
Aamir Fazil and Anna M. Lammerding, all of whom work in the Science to
Policy Division, Laboratory for Foodborne Zoonoses, Public Health
Agency of Canada.
In their study, the three researchers developed a stochastic,
quantitative risk assessment model to evaluate the public health risks
associated with consumption of ground beef and beef cuts contaminated
with Escherichia coli (E. coli) O157:H7 in Canada. The researchers evaluated the relative effects of
pre-harvest and processing interventions on public health risks,
comparing the baseline risks from consumption of beef products.
The research included findings from critical systematic review and
meta-analysis of published literature, and 20 different intervention
scenarios were assessed. The pre-harvest interventions that were
assessed included probiotics, an SRP vaccine, and a Type III protein
vaccine. Production/processing interventions that were analyzed
included hot water wash, steam pasteurization, acid spray chill,
dry-aged chill, and water spray chill. The researchers concluded that
the most effective strategy for E. coli O157:H7 management includes a pre-harvest intervention and several
processing interventions: "Specifically, application of Type III
secreted protein vaccination along with a suite of processing
interventions provided the greatest relative reduction in risks." The
Company's EconicheTM vaccine is a Type III protein vaccine.
The findings from this study support the Company's ongoing efforts to
gain widespread uptake of cattle vaccination with EconicheTM.
EconicheTM Regulatory/Market Update
Since October, 2008, the Company has had a full license for its cattle
vaccine against E. coli O157 - EconicheTM - in Canada. In the intervening period, there has been limited uptake by
Canadian cattle producers. Those who have adopted the technology have
been small producers who have a branded beef product and are concerned
about the negative impact of an E. coli outbreak on their brand, and those producers/farmers whose cattle have
infected humans with E. coli O157. Outbreaks and recalls associated with E. coli O157 infection and contamination continue to occur on a regular basis,
so this public health threat remains a grave concern.
In February, 2008, the Company was advised by the United States
Department of Agriculture (USDA) that EconicheTM was eligible for a conditional license once certain conditions were met.
Since that time, the Company has been in regular dialogue with USDA
officials about this license.
Most recently, the USDA's Center for Veterinary Biologics issued updated
guidance regarding the licensing of vaccines as pre-harvest food safety
interventions. Company representatives look forward to discussing this
new guidance with the USDA, to collaboratively reach consensus on the
path to vaccine licensing in the U.S.
About E. coli O157
Ruminants, primarily cattle, are considered to be the primary carriers
of E. coli O157. This bacterium can cause severe illness and can even be fatal when
ingested by humans from contaminated meat, vegetables, other food
products, or water. Human exposure and infection with E. coli O157 can result in serious health consequences, including abdominal
pain and severe bloody diarrhea. In severe cases, kidney damage can
occur and progress to serious complications and even death. Lingering,
long-term medical conditions can persist in individuals exposed to the
bacterium. These include post-infectious irritable bowel syndrome
(PI-IBS), reduced kidney function, diabetes, hypertension and reactive
An estimated 100,000 cases of human infection with the E. coli O157 organism are reported each year in North America. Two to seven per
cent of those people develop haemolytic uremic syndrome (HUS), a
disease characterized by kidney failure. Five percent of HUS patients
die, many of them children and senior citizens, whose kidneys are more
sensitive to damage. Among the many outbreaks recorded, a 1996 Japanese
outbreak made more than 9,000 people sick while the Walkerton, Ontario
outbreak in 2000 sickened 2,500. A late April E. coli outbreak in New Brunswick has sickened up to 27 residents, many of whom
ate at a Jungle Jim's restaurant.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company's primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small
and Medium-Sized Employers in Canada for 2011. For more information,
please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.